FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for solid tumours
The US FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for adults with HER2-positive solid tumours.
The US FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for adults with HER2-positive solid tumours.
What's Your Reaction?
